Skip to main content
GSK
NYSE Life Sciences

GSK's Momelotinib Receives Orphan Drug Designations for Life-Threatening VEXAS Syndrome

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$53.2
Mkt Cap
$105.524B
52W Low
$35.45
52W High
$61.695
52W Position info
50% above low
Off High info
14% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

GSK sits 50% above its 52-week low of $35.45.

Summary

GSK's momelotinib received Orphan Drug Designations from US and EU regulators for VEXAS syndrome, a rare and life-threatening condition with no approved treatments, supporting its advanced development.


Key Events · Product Development and Regulatory · GSK

  • Orphan Drug Designations Granted

    Momelotinib received Orphan Drug Designation (ODD) from both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of VEXAS syndrome.

  • Addresses High Unmet Medical Need

    VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with a 30-40% five-year mortality rate and currently no approved treatment options.

  • Advanced Clinical Development

    A planned Phase II/III ATLAS trial is underway to evaluate momelotinib's efficacy and safety in VEXAS syndrome, supporting future global regulatory submissions.

  • Existing Drug with Differentiated Mechanism

    Momelotinib (Ojjaara/Omjjara) is already approved in the US, EU, UK, and Japan for myelofibrosis and has a differentiated mechanism of action.


Analysis · GSK · Life Sciences

The US FDA and EMA granting Orphan Drug Designations for momelotinib in VEXAS syndrome is a significant positive for GSK's pipeline. VEXAS is a rare, severe, and currently untreatable condition, meaning these designations provide regulatory support and potential market exclusivity for a drug addressing a high unmet medical need. The ongoing Phase II/III ATLAS trial will further evaluate momelotinib's potential in this indication.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GSK was trading at $53.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $105.5B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GSK - Latest Insights

GSK
Oct 28, 2026, 11:45 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $48.75
Real-time Price: $50.45 info
Change: +$1.70 (+3%) info
Market Cap: $101.406B info
GSK
Oct 28, 2026, 10:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $49.08
Real-time Price: $50.45 info
Change: +$1.37 (+3%) info
Market Cap: $101.406B info
GSK
Oct 28, 2026, 3:42 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $51.20
Real-time Price: $50.45 info
Change: -$0.750 (-1%) info
Market Cap: $101.406B info
GSK
Oct 26, 2026, 12:16 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.12
Real-time Price: $50.45 info
Change: -$0.665 (-1%) info
Market Cap: $101.406B info
GSK
Oct 26, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.04
Real-time Price: $50.45 info
Change: -$0.590 (-1%) info
Market Cap: $101.406B info